TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01888003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Transfusion
Description: An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb \< 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Transfusion
Description: An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb \< 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Transfusion
Description: An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb \< 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
Study: NCT00504036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inflatable intra-gastric balloon
Description: inflatable intra-gastric balloon
Study: NCT04652180

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
Study: NCT02017171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive oral tablets identical in appearance to allopurinol tablets.
Study: NCT00951782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency TMS
Description: deep TMS HADD coil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency TMS
Description: deep TMS HADD coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: sham deep TMS HADD coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: sham deep TMS HADD coil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency TMS
Description: Deep TMS - HADD coil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency TMS
Description: Deep TMS - HADD coil
Study: NCT01983150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crush the Crave Application
Description: Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: On the Road to Quitting - Self Help
Description: The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide.
Study: NCT03462290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin type A
Description: Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
Study: NCT02398409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths
Description: Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 8 week telephone usual care with education with nurse case manager
Study: NCT03844477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection QLB(quadratus lumborum block)
Description: Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified.
Study: NCT04136756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255 Q21
Description: NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
Study: NCT03633721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: 7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: 7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: 7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: 7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
Study: NCT02516189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training program
Description: Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.~Relaxation: 5 minutes of stretching.
Study: NCT06779786

Intervention type: OTHER
Group type: OTHER
Intervention: Group 1 (Aromatherapy Groups):
Description: Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of eucalyptus sttriodora (Group 1) oil, diluted with 3% sesame oil, is dropped into the palm of the hand, and after rubbing the hands together, rub the earlobe from top to bottom with the thumb and index finger for four minutes. Massage application together and again by dropping 2 ml of 3% eucalyptus sttriodora (Intervention 1) oil into the palm. These are groups that are given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands mutually.

Intervention type: OTHER
Group type: OTHER
Intervention: Group 2 (Aromatherapy Groups):
Description: Group 2(Aromatherapy Groups): Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of medicanal lavandula (Group 2) oil, diluted with 3% sesame oil, is dropped into the palm of the hand, and after rubbing the hands together, rub the earlobe from top to bottom with the thumb and index finger for four minutes. Massage application together and again by dropping 2 ml of 3% medicanal lavandula (Intervention 1) oil into the palm. These are groups that are given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands mutually.
Study: NCT02011945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT04006756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training 1
Description: Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online cognitive training 2
Description: Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
Study: NCT00401830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet administered twice daily
Study: NCT00057577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
Study: NCT06779786

Intervention type: OTHER
Group type: OTHER
Intervention: Group 3 (Placebo Control Group)
Description: Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of sesame oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the earlobe from top to bottom with the thumb and index finger for four minutes, and again apply 2 ml of sesame oil into the palm. The group was given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands together with the drops.
Study: NCT00057577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications
Description: Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications
Description: Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Study: NCT04136756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously at specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously at specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab administered subcutaneously at specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab administered subcutaneously at specified dose on specified days
Study: NCT00248885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regulating Mean Arterial Pressure during cardiopulmonary bypass
Description: Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regulating Mean Arterial Pressure during cardiopulmonary bypass
Description: Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
Study: NCT02503995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Participation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise Participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Participation
Study: NCT03680469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard early rehabilitation
Description: The standard early rehabilitation program is an intervention regularly utilized in the stroke center of National Taiwan University Hospital. Activities performed in the standard early rehabilitation program within 24-72 hours of onset include(1) bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and facilitation techniques, and (2) functional training in which the patients are instructed to engage in the repetitive and systematic practice of tasks, such as rolling or sitting supported on the bed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard early rehabilitation
Description: The standard early rehabilitation program is an intervention regularly utilized in the stroke center of National Taiwan University Hospital. Activities performed in the standard early rehabilitation program within 24-72 hours of onset include(1) bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and facilitation techniques, and (2) functional training in which the patients are instructed to engage in the repetitive and systematic practice of tasks, such as rolling or sitting supported on the bed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adding early out-of-bed mobilization
Description: Early mobilization treatment involving out-of-bed, task-specific activities including rolling and sitting up, sitting unsupported out of bed, and standing within 24-72 hours of onset and accounting for more than two thirds of the treatment time in early rehabilitation .
Study: NCT00873860

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 150 mg
Description: CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 300 mg
Description: CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 600 mg
Description: CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
Study: NCT01500343

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saccharomyces boulardii
Description: 1 gram per day, during 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: 1 gram per day, during 3 months
Study: NCT00003950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Study: NCT00708071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)
Description: Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
Study: NCT01304784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Capecitabine, Trastuzumab and MM-111
Description: Conventional chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib +/- Trastuzumab and MM-111
Description: Conventional chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Trastuzumab and MM-111
Description: Conventional chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib, trastuzumab, paclitaxel, and MM-111
Description: Conventional chemo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, trastuzumab and MM-111
Description: Conventional chemotherapy